期刊文献+

特发性肺间质纤维化患者血清细胞因子的检测及其意义 被引量:2

Detection and significance of serum cytokines levels in patients with idiopathic pulmonary fibrosis
下载PDF
导出
摘要 目的探讨血清TGF-β1、IL-13水平在特发性肺间质纤维化(IPF)发生发展中的意义。方法采用双抗体夹心ELISA法检测36例IPF患者治疗前与治疗3个月后血清中TGF-β1、IL-13水平。结果IPF患者血清TGF-β1、IL-13水平明显高于正常对照组(P<0.05)。血清TGF-β1、IL-13水平治疗有效组较治疗前降低(P<0.05),治疗无效组较治疗前升高(P<0.05)。无效恶化组血清TGF-β1、IL-13水平明显高于有效组(P<0.05)。结论IPF患者体内高水平的TGF-β1、IL-13与IPF的发生发展密切相关,有可能作为检测病情,判断疗效的客观指标以及IPF的辅助诊断指标。 Objective To investigate the significance of expression of transforming LigTowth factor β1 (TGF-β1) and interleukin- 13 in serum of patients with idiopathic pulmonary fibrosis(IPF). Methods The serum levels of TGF-β1 and IL-13 in 36 patients with IPF were detected by ELISA before and after 3 - month treatment. Results The serum levels of TGF-β1 and IL-13 in patients with IPF were significantly higher than those of control group. In the effective group, the serum TGF-β1 and IL-13 levels were decreased, as compared with. In the non-effectivegToup, the serum TGF-β1 and IL-13 levels were increased. The serum TGF-β1 and IL-13 levels in effective group were decreased, as compared with those in non - effective group. Conclusion The increase of TGF-β1 and IL-13 levels is related in the development and progression of IPF. TheLiserum TGF-β1 and IL-13 levels might represent some useful parameters in monitoring the changes of disease state and evaluating therapeutic effect on IPF.
出处 《河北医药》 CAS 2007年第5期436-437,共2页 Hebei Medical Journal
基金 石家庄市科技局计划项目(编号:061461223)
关键词 特发性肺间质纤维化 转化生长因子-Β1 白介素-13 idiopathic pulmonary fibrosis transforming growth factor-β1 interleukin-13
  • 相关文献

参考文献7

  • 1Khalil N,O'Connor R.Idiopathic pulmonary fibrosis:current understanding of the pathogenesis and the status of treatment.CMAJ,2004,171:153-160.
  • 2American Thoracic Society.Idiopathic pulmonary fibrosis:diagnosisand treatment.International consensus statement.Am J Respir Crit Care Med,2000,161:646-664.
  • 3Santana A,Saxena B,Noble NA,et al.Increased expression of trans forming growth factor beta isoforms (beta 1,beta 2,beta 3) in bleomycin-induced pulmonary fibrosis.Am J Respir Cell Mol Biol,1995,13:34-44.
  • 4Broekelmann TJ,Limper AH,Colby TV,et al.Transforming growth factors-β1is present at sites of extracellular gene expression in human pulmonary fibrosis.Proc Natl Acad Sci USA,1991,88:6642-6646.
  • 5Yong SJ,Adlakha A,Limper AH.Circulating transforming growth factor-1.Chest,2001,120:68-70.
  • 6肖莉,李振华,侯显明,于润江.特发性肺纤维化患者支气管肺泡灌洗液中白细胞介素13的水平及意义[J].中华结核和呼吸杂志,2003,26(11):686-688. 被引量:8
  • 7Strieter RM.Mechanisms of pulmonary fibrosis:conference summary.Chest,2001,120:77-85.

二级参考文献10

  • 1Lee CG, Homer RJ,Zhu Z, et al.Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor bate. J Exp Med,2001,194:809-821.
  • 2Hancock A, Armstrong L,Gama R,et al. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol, 1998, 18:60-65.
  • 3Chiaramonte MG, Donaldson DD, Cheever AW, et al. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest, 1999, 104:777-785.
  • 4Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion subepi- thelial fibrosis, physiological abnormalities and eotaxin production. J Clin Invest, 1999, 103:779-788.
  • 5American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment international consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med, 2000, 161(2 Pt 1):646-664.
  • 6Wooley KL, Adelroth E, Woolley MJ, et al. Granulocyte-Macrophage colony-stimulating factor, eosinophils and eosinophil cationic protein in subjects with and without mild, stable, atopic asthma. Eur Respir J, 1994, 7:1576-1584.
  • 7Oriente A, Fedarko NS, Pacocha SE, et al. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther, 2000, 292:988-994.
  • 8李振华,孙吉臻.弥漫性间质性肺疾病支气管—肺泡灌洗液细胞学检查...[J].中华内科杂志,1990,29(1):2-4. 被引量:16
  • 9特发性肺(间质)纤维化诊断和治疗指南(草案)[J].中华结核和呼吸杂志,2002,25(7):387-389. 被引量:633
  • 10于润江.间质性肺疾病的分类[J].中华结核和呼吸杂志,2002,25(9):516-519. 被引量:20

共引文献7

同被引文献13

  • 1朱剑萍,姚宏伟,陈季强.TGF-β_1诱导肺切片纤维化模型的建立[J].中国药理学通报,2006,22(4):501-504. 被引量:8
  • 2李振华.特发性肺纤维化的治疗[J].中华结核和呼吸杂志,2007,30(4):250-252. 被引量:5
  • 3朱文珏 陈文彬.呼吸病学[M].北京:人生卫生出版社,2003.993.
  • 4Antoniou KM, Alexandrakis MG, Siafakas NM, et al. Cytokine network in the pathogenesis of idiopathic pulmonary fibrosis [J]. Sarcoidosis Vase Diffuse Lung Dis, 2005, 22 (2): 91-104.
  • 5Shimizu Y, Kuwabara H, Ono A, et al. Intracellular Th1/ Th2 balance of pulmonary CD4 (+) T cells in patients with active interstitial pneumonia evaluated by serum KL-6 [J]. Immunopharmacol Immunotoxicol, 2006, 28 (2): 295-304.
  • 6Papiris SA, Kollintza A, Kitsanta P, et al. Relationship of BAL and lung tissue CD4^+ and CD8^+ T lymphoeytes, and their ratio in idiopathic pulmonary fibrosis [J]. Chest, 2005, 128 (4): 2971-2977.
  • 7Tsoutsou PG, Gourgoulianis KI, Petimaki E, et al. Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis [J]. Respir Med, 2006, 100 (5): 938-945.
  • 8ATS/ERS. Idiopathic pulmonary fibrosis: diagnosis and treatment of international consensus statement [J]. Am J RespirCrit CareMed, 2000, 161: 646-664.
  • 9Bouros D, Antoniou KM, Tzouvelekis A, et al. Interferongamma lb for the treatment of idiopathic pulmonary fibrosis [J].Expert Opin Biol Ther, 2006, 6 (10): 1051-1060.
  • 10Khalil N, O'Connor R. Idiopathic pulmonary fibrosis:current under-standing of the pathogenesis and the status of treatmentfj]. CMAJ,2004,171(2):153-160.

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部